Chimeric antigen receptor T-cell therapy for multiple myeloma: A consensus statement from the European Myeloma Network

Moreau P, Sonneveld P, Boccadoro M, Cook G, Victoria Mateos M, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Blade J, Delforge M, Hajek R, Ludwig H, Facon T, San Miguel JF, Einsele H (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Book Volume: 104

Pages Range: 2358-2360

Journal Issue: 12

DOI: 10.3324/haematol.2019.224204

Abstract

A doptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved in relapsed/refractory MM, it will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in MM, and discusses several important issues for its future development.

Involved external institutions

Nantes University Hospital / Centre hospitalier universitaire de Nantes (CHU) France (FR) Erasmus University Medical Center (MC) Netherlands (NL) University of Turin / Università degli Studi di Torino (UNITO) Italy (IT) University of Leeds United Kingdom (GB) University of Salamanca / Universidad de Salamanca Spain (ES) Karolinska Institute Sweden (SE) Universitätsklinikum Heidelberg Germany (DE) National and Kapodistrian University of Athens Greece (GR) Champalimaud Foundation / Fundação Champalimaud Portugal (PT) Hospital Clínic de Barcelona Spain (ES) Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven Belgium (BE) University of Ostrava / Ostravská univerzita v Ostravě Czech Republic (CZ) Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille) France (FR) Universidad de Navarra Spain (ES) Julius-Maximilians-Universität Würzburg Germany (DE)

How to cite

APA:

Moreau, P., Sonneveld, P., Boccadoro, M., Cook, G., Victoria Mateos, M., Nahi, H.,... Einsele, H. (2019). Chimeric antigen receptor T-cell therapy for multiple myeloma: A consensus statement from the European Myeloma Network. Haematologica, 104(12), 2358-2360. https://doi.org/10.3324/haematol.2019.224204

MLA:

Moreau, Philippe, et al. "Chimeric antigen receptor T-cell therapy for multiple myeloma: A consensus statement from the European Myeloma Network." Haematologica 104.12 (2019): 2358-2360.

BibTeX: Download